Develop and commercialize diagnostic tests for gynecologic diseases. Provide OVA1, OVERA, and OVA1plus to detect the risk of ovarian malignancy. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 8% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $9.2M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 21 buys and 16 sells. Management buying with its own money is usually read as a good sign.
A loss of $12.8M against $9.2M in annual sales.
The stock sits at $0.08. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2 times as much as the market average. Big rallies — and big drops — can both happen fast.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.